Skip to main content Accessibility help
×
Home

Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak

  • S. H. LEE (a1), J.-J. YIM (a2), H. J. KIM (a3), T. S. SHIM (a4), H. S. SEO (a5), Y. S. CHO (a5), H.-K. LEE (a1), Y. M. LEE (a1), E. J. LEE (a6) and W. J. LEW (a3) (a7)...

Summary

We screened tuberculosis (TB) contacts as an outbreak investigation with tuberculin skin test (TST) and interferon-gamma release assay (IGRA). We evaluated adverse events and TB incidence in all persons screened after rifampicin (RFP) prophylaxis, and specifically assessed the new TB cases in relation to initial TST and IGRA results. The 180 contacts were divided into four groups: TST+/IGRA+ (n=101), TST+/IGRA− (n=22), TST−/IGRA+ (n=16), and TST–/IGRA– (n=41). RFP treatment (4 months) was prescribed only to the TST+/IGRA+ group. Of 87 contacts who initiated prophylaxis, adverse events occurred in 21 contacts (24·1%) including hepatotoxicity (11·5%), flu-like syndrome (5·7%), and thrombocytopenia (3·4%). TB developed in two TST+/IGRA+ subjects after completion of prophylaxis, including one multidrug-resistant (MDR)-TB case during 21·8 months of follow-up. Adverse events were frequent, and development of TB including MDR-TB occurred after RFP prophylaxis.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak
      Available formats
      ×

Copyright

Corresponding author

*Author for correspondence: W. J. Lew, M.D., Stop TB and Leprosy Elimination, World Health Organization, Office of the Representative, Bldg 3, DOH compound, Sta. Cruz, 1003 Manila, Philippines. (Email: leww@wpro.who.int)

References

Hide All
1.World Health Organization.The global plan to stop TB 2011–2015. Geneva: WHO, 2010. Report No. WHO/HTM/STB/2010.2 (http://www.who.int/tb/publications/2010/eng.pdf). Accessed 3 January 2011.
2.Corbett, EL, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Archives of Internal Medicine 2003; 163: 10091021.
3.Dye, C, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. Journal of the American Medical Association 1999; 282: 677686.
4.Broekmans, JF, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. European Respiratory Journal 2002; 19: 765775.
5.Jasmer, RM, Nahid, P, Hopewell, PC. Clinical practice. Latent tuberculosis infection. New England Journal of Medicine 2002; 347: 18601866.
6.American Thoracic Society/Centers for Disease Control and Prevention.Targeted tuberculin testing and treatment of latent tuberculosis infection. American Journal of Respiratory and Critical Care Medicine 2000; 161: S221–247.
7.Menzies, D, Pai, M, Comstock, G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Annals of Internal Medicine 2007; 146: 340354.
8.Pai, M, Zwerling, A, Menzies, D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Annals of Internal Medicine 2008; 149: 177184.
9.Bakir, M, et al. Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. Annals of Internal Medicine 2008; 149: 777787.
10.Yoshiyama, T, et al. Use of the QuantiFERON-TB Gold test for screening tuberculosis contacts and predicting active disease. International Journal of Tuberculosis and Lung Disease 2010; 14: 819827.
11.Kik, SV, et al. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. European Respiratory Journal 2010; 35: 13461353.
12.Diel, R, et al. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. American Journal of Respiratory and Critical Care Medicine 2008; 177: 11641170.
13.Mori, T, Harada, N. Cost-effectiveness analysis of QuantiFERON-TB 2nd generation used for detection of tuberculosis infection in contact investigations. Kekkaku 2005; 80: 675686.
14.Menzies, D, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Annals of Internal Medicine 2008; 149: 689697.
15.Menzies, D, et al. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. American Journal of Respiratory and Critical Care Medicine 2004; 170: 445449.
16.Blumberg, HM, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. American Journal of Respiratory and Critical Care Medicine 2003; 167: 603662.
17.Holdiness, MR. A review of blood dyscrasias induced by the antituberculosis drugs. Tubercle and lung disease 1987; 68: 301309.
18.Livengood, JR, et al. Isoniazid-resistant tuberculosis. A community outbreak and report of a rifampin prophylaxis failure. Journal of the American Medical Association 1985; 253: 28472849.
19.Balcells, ME, et al. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerging Infectious Diseases 2006; 12: 744751.
20.Lee, SH, et al. Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak. Respiratory Medicine 2010; 104: 448453.
21.Korea Center for Disease Control. National guidelines for managing tuberculosis. KCDC guideline 2007, pp. 133141.
22.Grosset, J, Leventis, S. Adverse effects of rifampin. Reviews of Infectious Diseases 1983; 5: S440S450.
23.Blajchman, MA, et al. Rifampicin-induced immune thrombocytopenia. British Medical Journal 1970; 3: 2426.
24.Martnez, E, Collazos, J, Mayo, J. Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine 1999; 78: 361369.
25.Girling, DJ. Adverse reactions to rifampicin in antituberculosis regimens. Journal of Antimicrobial Chemotherapy 1977; 3: 115132.
26.LoBue, PA, Moser, KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. American Journal of Respiratory and Critical Care Medicine 2003; 168: 443447.
27.Lobue, P, Menzies, D. Treatment of latent tuberculosis infection: an update. Respirology 2010; 15: 603622.
28.Anon.A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. American Review of Respiratory Disease 1992; 145: 3641.
29.Villarino, ME, et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. American Journal of Respiratory and Critical Care Medicine 1997; 155: 17351738.
30.Polesky, A, et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. American Journal of Respiratory and Critical Care Medicine 1996; 154: 14731477.
31.Nolan, CM, et al. Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees. American Review of Respiratory Disease 1986; 133: 431436.
32.Bai, GH, et al. Trend of anti-tuberculosis drug resistance in Korea, 1994–2004. International Journal of Tuberculosis and Lung Disease 2007; 11: 571576.
33.Lee, S, et al. The role of chest CT scanning in TB outbreak investigation. Chest 2010; 137: 10571064.

Keywords

Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak

  • S. H. LEE (a1), J.-J. YIM (a2), H. J. KIM (a3), T. S. SHIM (a4), H. S. SEO (a5), Y. S. CHO (a5), H.-K. LEE (a1), Y. M. LEE (a1), E. J. LEE (a6) and W. J. LEW (a3) (a7)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed